Loading stock data…
Relmada Therapeutics (RLMD)
$6.98+0.29 (+4.33%)
After Hours$6.98+0.00 (+0.00%)· Last close Jun 29
Relmada Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Relmada Therapeutics, Inc. in the Healthcare sector is trading at $6.98 with a market capitalization of $675M. Wall Street consensus targets $12.67 (6 analysts), implying a +81.5% move over the next 12 months. The stock is currently near its 52-week high of $8.00, remaining 46.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +81.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.46M↑ | -$20.33M↓ | -$10.33M↓ | -$10.22M↑ | -$18.22M |
| Net Income | -$19.05M↑ | -$19.87M↓ | -$10.09M↓ | -$9.87M↑ | -$17.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$675.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.92%
Volume
Today's trading volume
2.28M
Recent News
Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data for its NDV-01 candidate, which showed a 95% complete response rate in high-risk non-muscle invasive bladder cancer. The company is well-capitalized with $234 […]
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...
Relmada Therapeutics Inc (RLMD) showcases robust clinical data and strategic financial moves, despite facing increased expenses and net loss.
Relmada Therapeutics Q1 Earnings Call Highlights
Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing. On the company’s first-q
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.